semaglutide mash approval The FDA has approved Wegovy (semaglutide) as a treatment for metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program Health Canada has approved Wegovy®

Effect of milk protein intake and casein-to-whey ratio in breakfast meals on postprandial glucose, satiety ratings, and subsequent meal intake

In analyses stratified according to age at baseline, we observed reduced HRs for prostate cancer with GLP-1RA vs basal insulin use among older men (65 years, 70 years) in both the ITT and per-protocol analyses

CrossRef Editorial: Advancing immune research in chronic liver diseases through new approach methodologies Sara Massironi, Ana C

I've had some low-level nausea and can't eat mustard (no idea why) or orange pekoe tea, but I've been able to eat and drink pretty much everything else

It works as a key, allowing the sugar to go from the blood and into the cell

At 12mg weekly using 20mg vials reconstituted with 1mL (20mg/mL), each dose requires 60 units, and each vial provides approximately 1.7 weekly doses